ATE359516T1 - Verwendung des proteins crabp ii (cellular retinoic acid-binding protein ii) als marker für brustkrebs - Google Patents

Verwendung des proteins crabp ii (cellular retinoic acid-binding protein ii) als marker für brustkrebs

Info

Publication number
ATE359516T1
ATE359516T1 AT04739585T AT04739585T ATE359516T1 AT E359516 T1 ATE359516 T1 AT E359516T1 AT 04739585 T AT04739585 T AT 04739585T AT 04739585 T AT04739585 T AT 04739585T AT E359516 T1 ATE359516 T1 AT E359516T1
Authority
AT
Austria
Prior art keywords
breast cancer
protein
retinoic acid
binding protein
cellular retinoic
Prior art date
Application number
AT04739585T
Other languages
English (en)
Inventor
Gabriele Pestlin
Herbert Andres
Peter Berndt
Marie-Luise Hagmann
Johann Karl
Hanno Langen
Werner Zolg
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE359516T1 publication Critical patent/ATE359516T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70567—Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57473—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving carcinoembryonic antigen, i.e. CEA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT04739585T 2003-06-06 2004-06-04 Verwendung des proteins crabp ii (cellular retinoic acid-binding protein ii) als marker für brustkrebs ATE359516T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03012942 2003-06-06

Publications (1)

Publication Number Publication Date
ATE359516T1 true ATE359516T1 (de) 2007-05-15

Family

ID=33547585

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04739585T ATE359516T1 (de) 2003-06-06 2004-06-04 Verwendung des proteins crabp ii (cellular retinoic acid-binding protein ii) als marker für brustkrebs

Country Status (8)

Country Link
US (1) US7579158B2 (de)
EP (1) EP1636584B1 (de)
JP (1) JP4282086B2 (de)
AT (1) ATE359516T1 (de)
CA (1) CA2524708C (de)
DE (1) DE602004005859T2 (de)
ES (1) ES2285469T3 (de)
WO (1) WO2004111650A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060003391A1 (en) * 2003-08-11 2006-01-05 Ring Brian Z Reagents and methods for use in cancer diagnosis, classification and therapy
US20050112622A1 (en) * 2003-08-11 2005-05-26 Ring Brian Z. Reagents and methods for use in cancer diagnosis, classification and therapy
WO2005124360A2 (en) * 2004-06-18 2005-12-29 Roche Diagnostics Gmbh Use of protein tebp as a marker for breast cancer
US20080131916A1 (en) * 2004-08-10 2008-06-05 Ring Brian Z Reagents and Methods For Use In Cancer Diagnosis, Classification and Therapy
US20090155790A1 (en) * 2007-09-12 2009-06-18 Elias Georges Crab-pii directed diagnostics for neoplastic disease
EP2073010A1 (de) * 2007-12-17 2009-06-24 Atlas Antibodies AB Mittel zur Auswahl einer Brustkrebsbehandlung
US20250326723A1 (en) * 2021-10-22 2025-10-23 Northwestern University Development of an Enzyme-Inhibitor Reaction Using Cellular Retinoic Acid Binding Protein II for One-Pot Megamolecule Assembly

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5871909A (en) * 1991-08-30 1999-02-16 The Regents Of The University Of Michigan Human cellular retinoic acid binding protein I and II DNA and methods of use
US6579973B1 (en) 1998-12-28 2003-06-17 Corixa Corporation Compositions for the treatment and diagnosis of breast cancer and methods for their use
WO2002023200A2 (en) 2000-09-11 2002-03-21 Ciphergen Biosystems, Inc. Human breast cancer biomarkers
JP2005503760A (ja) 2001-01-24 2005-02-10 プロテイン デザイン ラブス， インコーポレイテッド 乳癌の診断方法、組成物および乳癌のモジュレーターのスクリーニング方法
AU2002255880A1 (en) 2001-03-22 2002-10-08 Mt. Sinai School Of Medicine Aberrantly expressed proteins in laser capture microdissected tumors
WO2002101075A2 (en) 2001-06-13 2002-12-19 Millennium Pharmaceuticals, Inc. Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer
WO2003004989A2 (en) * 2001-06-21 2003-01-16 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer

Also Published As

Publication number Publication date
US20060141543A1 (en) 2006-06-29
US7579158B2 (en) 2009-08-25
EP1636584B1 (de) 2007-04-11
WO2004111650A1 (en) 2004-12-23
ES2285469T3 (es) 2007-11-16
DE602004005859D1 (de) 2007-05-24
CA2524708A1 (en) 2004-12-23
CA2524708C (en) 2009-10-06
EP1636584A1 (de) 2006-03-22
DE602004005859T2 (de) 2007-12-13
JP4282086B2 (ja) 2009-06-17
JP2006526149A (ja) 2006-11-16

Similar Documents

Publication Publication Date Title
ATE554389T1 (de) Apex als marker für lungenkrebs
ATE471512T1 (de) Verwendung des proteins s100a 12 als marker für kolorektalkarzinom
KR100711046B1 (ko) 대장암에 대한 마커로서의 니코틴아미드ｎ―메틸트랜스퍼라아제의 용도
DE602006007703D1 (de) Verbesserte immuntestverfahren
ATE461449T1 (de) Verfahren zum nachweis von medizinisch relevanten zuständen in gelösten lbc-proben
WO2012050365A3 (ko) 교모세포종의 진단 또는 예후 예측용 바이오 마커 및 그 용도
ATE415486T1 (de) Verfahren zur messung der geschwindigkeiten des cholesterinrückwärtstransports in vivo als index für anti-artherogenese
DE602007006671D1 (de) Verwendung von nnmt als marker für lungenkrebs
ATE430936T1 (de) Verwendung von cyfra 21-1 und osteopontin als marker für kolorektalkarzinome
ATE418072T1 (de) Verfahren zur diagnose von gebärmutterhalskrebs
ATE359516T1 (de) Verwendung des proteins crabp ii (cellular retinoic acid-binding protein ii) als marker für brustkrebs
DE602004017317D1 (de) Verwendung der proteine proteinase 3 (prn3) und leukozyten elastatse inhibitor (ileu) als marker für kolorektale karzinome
ATE534037T1 (de) Verwendung des proteins asc als marker für brustkrebs
DE602006013333D1 (de) Kit und verfahren zum nachweis von urothelkarzinom
ATE503846T1 (de) Verfahren zur diagnose eines ovarialkarzinoms
IN2014MN00949A (de)
ATE353544T1 (de) Verwendung des proteins masp als marker für kolorektale karzinome
SG11201811433TA (en) Mmp1 gene transcript for use as marker for diagnosis of ovarian cancer prognosis, and test method
WO2010000467A8 (en) Asc as a marker for lung cancer
ATE393393T1 (de) Verwendung des proteins spee als marker für brustkrebs
FR2930036B1 (fr) Procede de diagnostic d'une hypertension arterielle pulmonaire.
ATE426168T1 (de) Verwendung von asc als marker fur kolorektalkarzinome
DE602004011228D1 (de) Verfahren und zusammensetzungen zur bestimmung glycierter proteine
ATE410691T1 (de) Verwendung des proteins proteasome aktivator untereinheit 3 als marker für kolorektale karzinome
ATE529745T1 (de) Verfahren zur bewertung des hautempfindlichkeitsniveaus durch verwendung von mit plattenepithelkarzinom zusammenhängendem antigen als indikation

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1636584

Country of ref document: EP